ClinicalTrials.gg
Active, not recruitingNCT04214262Updated Nov 18, 2026Results posted

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

A Phase 3 interventional study of Atezolizumab and Biospecimen Collection in Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 and Stage II Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 390 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 27, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 27 under way, 5 of them phase 3. atezolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 81
417 · median 80
Started
2020
with 8 others
Phase 3
18 of 81
1 open now
Primary completion
2024-08
later than 1 of 26 live
Registered
50th of 81
by date
Lead sponsor
6 of 81
National Cancer Institute (NCI)

Among the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 9 that started in 2020, is one of 18 in phase 3, reaches primary completion later than 1 of the 26 other live ones, and was the 50th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 6 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing atezolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.

SECONDARY OBJECTIVES:

I. To compare investigator-assessed progression-free survival (IA-PFS) between the arms.

II. To compare progression free survival (PFS) by blinded independent centralized review (BIRC) between the arms in a random subset of patients.

III. To evaluate distant, locoregional, and local failure rates within each treatment arm.

IV. To evaluate the frequency and severity of toxicities within each treatment arm.

ADDITIONAL OBJECTIVE:

I. To collect specimens for banking.

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OBJECTIVE:

I. This objective will not be met, as the study was closed following the first interim analysis.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or once daily (QD) over 1-3 weeks. Patients undergo fludeoxyglucose F-18 (FDG)-positron emission tomography/computed tomography (PET/CT) during screening. Patients undergo blood sample collection and CT scans throughout the trial.

ARM B: Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.

After completion of study treatment, patients are followed for 5 years after randomization.

03

Conditions studied

  • Lung Non-Small Cell Carcinoma
  • Stage I Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient must have or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0). Patient may have T3 disease with the exclusion of pericardial involvement. Patients with multifocal tumors with no more than two lesions confirmed or suspected to be synchronous early stage NSCLCs are eligible provided at least one lesion is histologically or cytologically proven to be NSCLC and meets one or more high-risk features
  • Disease must have one or more of the following high-risk features:

    • Tumor diameter >= 2 cm (inclusive of any non-solid, ground glass component) as assessed by diagnostic CT
    • Tumor standard uptake value (SUV) max >= 6.2 as assessed by FDG PET/CT
    • Moderately differentiated, poorly differentiated, or undifferentiated histology
  • Patient must have undergone diagnostic chest CT with or without contrast (IV contrast preferred) within 42 days prior to randomization. PET-CT may be used if the CT portion is of comparable diagnostic quality to a stand-alone CT. All disease must be assessed within 42 days prior to randomization
  • Patient must have undergone FDG PET/CT of chest within 90 days prior to randomization
  • Patient must not have evidence of hilar or mediastinal nodal involvement. Any patient with radiographically suspicious hilar or mediastinal nodes (including features such as non-calcified nodes with a short axis diameter > 1 cm, abnormal morphology, and/or elevated FDG avidity) must undergo cytologic sampling of suspicious nodes to rule out involvement prior to randomization. Mediastinal nodal sampling for other patients is optional. For cases in which the treating physician/multidisciplinary opinion is used to define nodes as "non-suspicious" (such as long-standing, stable enlarged nodes from other medical causes), the rationale must be clearly documented within the medical record
  • Patient must have undergone history and physical examination within 28 days prior to randomization
  • Patient must be medically or surgically inoperable as documented by the evaluating thoracic surgeon or multi-disciplinary tumor board consensus OR patient's unwillingness to undergo surgical resection must be clearly documented
  • Patient must not have received any prior treatment for the current NSCLC diagnosis
  • Patient must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment
  • Patient must not have received treatment with systemic immunostimulatory or agents, including , within 14 days prior to randomization
  • Patient must be >= 18 years old
  • Patient must have Zubrod performance status of 0-2
  • Patient must have adequate liver function defined as (AST) and alanine aminotransferase (ALT) =\< 3 x institutional upper level of normal (IULN) within 28 days prior to randomization
  • Patient must have adequate renal function defined as calculated >= 30 mL/min using the following formula. The serum creatinine value used in the calculation must have been collected within 28 days prior to randomization
  • Patient must have (ANC), , and measured within 28 days prior to randomization. The purpose of these tests is to collect baseline values to compare with on-treatment values
  • Patient must have thyroid-stimulating hormone (TSH) measured within 28 days prior to randomization. The purpose of this test is to collect baseline values to compare with on-treatment values
  • Patient must not have significant cardiovascular disease ( [NYHA] class II or greater)
  • Patient must not have myocardial infarction within 90 days prior to randomization
  • Patient must not have unstable arrhythmias or unstable angina
  • Patient must not have known (LVEF) \< 40% within 28 days prior to randomization

    • NOTE: Assessment of LVEF by echocardiogram or multigated acquisition (MUGA) is not an eligibility requirement, but if a standard of care echocardiogram or MUGA was clinically indicated, the LVEF must not be \< 40% within 28 days prior to randomization
  • Patient must not have had an infection >= grade 3 ( [CTCAE] version 5.0) within 28 days prior to randomization
  • Patient must not have an active disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • Patient must be tested for within 28 days prior to randomization. Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection. Patients may have past or resolved HBV infection

    • Active HBV is defined as having a positive hepatitis B surface antigen (HBsAg) test
    • Past or resolved HBV is defined as having a negative HBsAG test and a positive total hepatitis B core antibody (HBcAb) test
  • Patient must be tested for within 28 days prior to randomization. Patient must not have active hepatitis C virus (HCV) infection

    • Active HCV is defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test
  • Patient must have pulmonary function testing to include, at a minimum, (FEV1) and Diffusing capability of carbon monoxide (DLCO) documented within 90 days prior to randomization
  • Patients with known (HIV) infection must be receiving anti-retroviral therapy and have an undetectable viral load at their most recent viral load test within 6 months prior to randomization
  • Patient must not have a history of interstitial lung disease or evidence of active pneumonitis on the screening chest CT
  • Patients must not have a prior or concurrent whose natural history or treatment has the potential (in the opinion of the treating physician) to interfere with the safety or efficacy assessment of the regimen
  • Patients must not be pregnant due to the potential teratogenic side effects of the protocol treatment. Women of and men must have agreed to use an effective method for the duration of protocol treatment, and for 5 months (150 days) after the last dose of atezolizumab. A woman is considered to be of "reproductive potential" if she has had a menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding must be discontinued prior to randomization
  • Patients of reproductive potential must have a negative serum pregnancy test within 14 days prior to randomization
  • Patients must not have known active tuberculosis
  • Patients must not have received a live, attenuated vaccine within 28 days prior to randomization

    • NOTE: All coronavirus disease 2019 (COVID-19) vaccines that have received Food and Drug Administration (FDA) approval or FDA emergency use authorization are acceptable
  • Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab
  • Patients must not have a known history of severe allergic, anaphylactic, or other reactions to chimeric antibodies, fusion proteins, or Chinese hamster ovary cell products or to any component of the atezolizumab formulation
  • Patient must agree to have specimens submitted for translational medicine and banking
  • Patients must be informed of the investigational nature of this study and must sign and give written in accordance with institutional and federal guidelines
  • As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • Patients who can complete quality of life instruments in English, French, or Spanish must agree to complete the questionnaires at the protocol-specified time points
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    Arm A (atezolizumab, SBRT)

    Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Starting on day 1 cycle 3, patients also undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.

    Drug: Atezolizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy

  • Active comparator
    Arm B (SBRT)

    Beginning 21 days after randomization, patients undergo SBRT for 3-8 treatments every 2 days or QD over 1-3 weeks. Patients undergo FDG-PET/CT during screening. Patients undergo blood sample collection and CT scans throughout the trial.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Stereotactic Body Radiation Therapy

Interventions

  • Given IV

    Also known as: MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • OtherFludeoxyglucose F-18

    Undergo FDG PET/CT

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationStereotactic Body Radiation Therapy

    Undergo SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Count of participants who have died, measured at two years from trial registration.

    Time frame: From date of registration up to two years

Secondary outcomes

  1. Incidence of Adverse Events

    Only adverse events that are possibly, probably or definitely related to study drug are reported.

    Time frame: Up to 5 years after registration

  2. IA-PFS

    Compare investigator-assessed progression-free survival (IA-PFS) between the arms. IA-PFS is defined as 20% increase in the longest diameter of the primary lung tumor over smallest measurement observed using the same techniques as baseline, as well as an absolute increase of at least 0.5 cm, accompanied by confirmatory study (unequivocal PET findings or biopsy) OR appearance of any new lesion/site OR death due to disease without prior documentation of progression OR unequivocal PET findings and/or biopsy confirming malignancy in the absence of growth.

    Time frame: From registration up to 5 years

  3. Progression Free Survival

    Compare PFS (progression free survival) by blinded independent centralized review (BIRC) between the arms in a random subset of patients. PFS is defined as time from date of randomization to date of first documentation of progression assessed by BICR, or death due to any cause. PFS-BICR-1 for patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression.

    Time frame: Up to 5 years from registration

  4. Distant, Locoregional, Local Failure Rates.

    Evaluate distant, locoregional, and local failure rates within each treatment arm. Treatment failure is defined as time from date of randomization to date of first documentation of investigator-assessed progression or symptomatic deterioration (as defined above), early discontinuation of treatment, or death due to any cause. Time to treatment failure for patients last known not to have failed treatment are censored at the date of last contact.

    Time frame: Up to 5 years from registration

07

Results

Posted Oct 6, 2026

Participant flow

414 participants were enrolled and 400 met eligibility requirements at the time of interim analysis dataset curation. 3 participants were enrolled after interim analysis (primary closure date) dataset curation and are not included in this participants flow.

Participant flow — Overall Study
MilestoneArm A (Atezolizumab, SBRT)Arm B (SBRT)
Started210207
Completed85167
Not completed12540
Withdrew: On treatment4616
Withdrew: Ineligible86
Withdrew: Adverse event161
Withdrew: Withdrawal by subject85
Withdrew: Progression70
Withdrew: Under review3211
Withdrew: Death10
Withdrew: Other - not protocol specified50
Withdrew: Enrolled after interim analysis data was curated21

Outcome measures

PrimaryOverall Survival

Count of participants who have died, measured at two years from trial registration.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival1914
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 1.76 · 99% CI 0.76 to 4.08
SecondaryIncidence of Adverse Events

Only adverse events that are possibly, probably or definitely related to study drug are reported.

Time frame:
Up to 5 years after registration

Results for this outcome have not been posted.

SecondaryIA-PFS

Compare investigator-assessed progression-free survival (IA-PFS) between the arms. IA-PFS is defined as 20% increase in the longest diameter of the primary lung tumor over smallest measurement observed using the same techniques as baseline, as well as an absolute increase of at least 0.5 cm, accompanied by confirmatory study (unequivocal PET findings or biopsy) OR appearance of any new lesion/site OR death due to disease without prior documentation of progression OR unequivocal PET findings and/or biopsy confirming malignancy in the absence of growth.

Time frame:
From registration up to 5 years

Results for this outcome have not been posted.

SecondaryProgression Free Survival

Compare PFS (progression free survival) by blinded independent centralized review (BIRC) between the arms in a random subset of patients. PFS is defined as time from date of randomization to date of first documentation of progression assessed by BICR, or death due to any cause. PFS-BICR-1 for patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression.

Time frame:
Up to 5 years from registration

Results for this outcome have not been posted.

SecondaryDistant, Locoregional, Local Failure Rates.

Evaluate distant, locoregional, and local failure rates within each treatment arm. Treatment failure is defined as time from date of randomization to date of first documentation of investigator-assessed progression or symptomatic deterioration (as defined above), early discontinuation of treatment, or death due to any cause. Time to treatment failure for patients last known not to have failed treatment are censored at the date of last contact.

Time frame:
Up to 5 years from registration

Results for this outcome have not been posted.

Post-hocOverall Survival for White Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival for White Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival for White Participants1413
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 1.4 · 95% CI 0.70 to 2.82Stratified by sex and ethnicity.
Post-hocOverall Survival in Non White Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival in Non White Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival in Non White Participants51
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 6.36 · 95% CI 0.76 to 53.0NOT stratified by sex and ethnicity
Post-hocOverall Survival in Male Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival in Male Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival in Male Participants96
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 1.66 · 95% CI 0.63 to 4.36Stratified by race and ethnicity
Post-hocOverall Survival in Female Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival in Female Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival in Female Participants108
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 1.93 · 95% CI 0.78 to 4.74Stratified by race and ethnicity
Post-hocOverall Survival in Non Hispanic Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to two years
Reported as:
Number · participants
Overall Survival in Non Hispanic Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival in Non Hispanic Participants1914
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) · Hazard ratio (hr): 1.82 · 95% CI 0.96 to 3.45Stratified by race and sex
Post-hocOverall Survival in Hispanic Participants

Reported as the count of participants who have died, measured at two years.

Time frame:
From date of registration up to 2 years
Reported as:
Number · participants
Overall Survival in Hispanic Participants
participantsArm A (Atezolizumab, SBRT)Arm B (SBRT)
Overall Survival in Hispanic Participants00
Statistical analysis
  • Arm A (Atezolizumab, SBRT) vs Arm B (SBRT) ·

Adverse events

Collected over Up to 5 years after registration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Atezolizumab, SBRT)49/200 (24.5%)42/193 (21.8%)188/193 (97.4%)
Arm B (SBRT)50/200 (25%)0/194 (0%)86/194 (44.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventArm A (Atezolizumab, SBRT)Arm B (SBRT)
HypoxiaRespiratory, thoracic and mediastinal disorders11/1930/194
Lung infectionInfections and infestations10/1930/194
DyspneaRespiratory, thoracic and mediastinal disorders6/1930/194
Respiratory failureRespiratory, thoracic and mediastinal disorders4/1930/194
DiarrheaGastrointestinal disorders3/1930/194
Acute kidney injuryRenal and urinary disorders3/1930/194
PneumonitisRespiratory, thoracic and mediastinal disorders3/1930/194
HypertensionVascular disorders3/1930/194
AnemiaBlood and lymphatic system disorders2/1930/194
Myocardial infarctionCardiac disorders2/1930/194
Most frequent other events
Showing 10 of 51
Most frequent other events
EventArm A (Atezolizumab, SBRT)Arm B (SBRT)
FatigueGeneral disorders97/19361/194
HyperglycemiaMetabolism and nutrition disorders61/1931/194
AnemiaBlood and lymphatic system disorders50/1933/194
DiarrheaGastrointestinal disorders50/1932/194
CoughRespiratory, thoracic and mediastinal disorders49/19318/194
Lymphocyte count decreasedInvestigations47/1933/194
DyspneaRespiratory, thoracic and mediastinal disorders43/19317/194
ConstipationGastrointestinal disorders36/1931/194
HypoalbuminemiaMetabolism and nutrition disorders36/1930/194
NauseaGastrointestinal disorders35/19310/194

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
Median72.1 (40.5 to 88.9)73.5 (52 to 91.2)72.6 (40.5 to 91.2)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
Female99117216
Male10183184
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
White168161329
Black182745
Asian4610
Native American224
Multi-racial123
Unknown729
Tumor Size
Tumor Size(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
<4cm172171343
>=4cm282957
Tumor Location
Tumor Location(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
Central6364127
Peripheral137136273
ECOG PS
ECOG PS(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
0-1177179356
2232144
Hispanic
Hispanic(Participants)Arm A (Atezolizumab, SBRT)Arm B (SBRT)Total
Yes8513
No186189375
Unknown6612
08

Study locations

390 sites

Showing the first 100 of 390 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Daly ME, Simone CB 2nd, Redman MW, Hsieh MH, Hesketh PJ, Hu C, Monjazeb AM, Steuer CE, Ganti AK, Kashani R, Bauman JR, Feliciano JL, Moon J, Ku K, Le-Lindqwister N, Baschnagel AM, Maraboyina S, Sherwood GB, Almquist D, Higgins KA, Gray JE, Bradley JD, Kelly K. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet. 2026 Sep 6:S0140-6736(26)01655-7. doi: 10.1016/S0140-6736(26)01655-7. Online ahead of print. PubMed 42702214 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2024, 48 months.

Results were first posted in Oct 2026, 2 years 1 month after primary completion.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's 48 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2019
First posted
Jan 2, 2020
StartActual
Aug 13, 2020
Primary completionActual
Aug 24, 2024
CompletionEst.
Jun 9, 2027
Results first posted
Oct 6, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Sites
21 sites added, 22 sites removed
Show 21 added (21 United States)
  • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
  • Lahey Clinic · Burlington, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
  • UT MD Anderson - The Woodlands · Conroe, United States
  • UT MD Anderson Cancer Center · Houston, United States
  • UT MD Anderson - West Houston · Houston, United States
  • UT MD Anderson - League City · League City, United States
  • UT MD Anderson - Sugar Land · Sugar Land, United States
  • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
  • Aspirus Cancer Care-Antigo-Volm Cancer Center · Antigo, United States
  • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton · Appleton, United States
  • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield · Brookfield, United States
  • Ascension Calumet Hospital-Chilton · Chilton, United States
  • Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson · Franklin, United States
  • Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon · Mequon, United States
  • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Milwaukee, United States
  • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh · Oshkosh, United States
  • Ascension All Saints Hospital-Spring Street-Racine · Racine, United States
  • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center · Rhinelander, United States
  • Aspirus Cancer Care-Wausau · Wausau, United States
  • Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa · Wauwatosa, United States
Show 22 removed
  • Saint Joseph Hospital East · Lexington, United States
  • Lahey Hospital and Medical Center · Burlington, United States
  • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
  • University of Pittsburgh Cancer Institute (UPCI) · Pittsburgh, United States
  • MD Anderson in The Woodlands · Conroe, United States
  • M D Anderson Cancer Center · Houston, United States
  • MD Anderson West Houston · Houston, United States
  • MD Anderson League City · League City, United States
  • MD Anderson in Sugar Land · Sugar Land, United States
  • West Virginia University Charleston Division · Charleston, United States
  • Langlade Hospital and Cancer Center · Antigo, United States
  • Ascension Saint Elizabeth Hospital · Appleton, United States
  • Ascension Southeast Wisconsin Hospital - Elmbrook Campus · Brookfield, United States
  • Ascension Calumet Hospital · Chilton, United States
  • Ascension Saint Francis - Reiman Cancer Center · Franklin, United States
  • Ascension Columbia Saint Mary's Hospital Ozaukee · Mequon, United States
  • Ascension Columbia Saint Mary's Hospital - Milwaukee · Milwaukee, United States
  • Ascension Mercy Hospital · Oshkosh, United States
  • Ascension All Saints Hospital · Racine, United States
  • Aspirus Cancer Care - James Beck Cancer Center · Rhinelander, United States
  • Aspirus Regional Cancer Center · Wausau, United States
  • Ascension Medical Group Southeast Wisconsin - Mayfair Road · Wauwatosa, United States
Oct 27, 2026
Enrollment
415→417
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: From date of randomization to date of death due to any cause, assessed up to 3 years → From date of registration up to two years
Oct 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42702214 ↗
Oct 6, 2026
Secondary outcomes
2 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedProgression free survivalFree SurvivalTime frame: From date of randomization to date of first documentation of progression or death due to any cause, assessed up to 5 years → Up to 5 years from registration
  • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 5 years → Up to 5 years after registration
  • AddedIA-PFSTime frame: From registration up to 5 years
  • AddedDistant, Locoregional, Local Failure Rates.Time frame: Up to 5 years from registration
  • Removedother outcomeChange in health-related quality of lifeTime frame: Up to 5 years
Oct 6, 2026
Show all 2 updates
  1. Oct 27, 2026
    21 sites added, 22 sites removed
    Show 21 added (21 United States)
    • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United States
    • Lahey Clinic · Burlington, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    • UT MD Anderson - The Woodlands · Conroe, United States
    • UT MD Anderson Cancer Center · Houston, United States
    • UT MD Anderson - West Houston · Houston, United States
    • UT MD Anderson - League City · League City, United States
    • UT MD Anderson - Sugar Land · Sugar Land, United States
    • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
    • Aspirus Cancer Care-Antigo-Volm Cancer Center · Antigo, United States
    • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton · Appleton, United States
    • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield · Brookfield, United States
    • Ascension Calumet Hospital-Chilton · Chilton, United States
    • Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson · Franklin, United States
    • Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon · Mequon, United States
    • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus · Milwaukee, United States
    • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh · Oshkosh, United States
    • Ascension All Saints Hospital-Spring Street-Racine · Racine, United States
    • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center · Rhinelander, United States
    • Aspirus Cancer Care-Wausau · Wausau, United States
    • Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa · Wauwatosa, United States
    Show 22 removed
    • Saint Joseph Hospital East · Lexington, United States
    • Lahey Hospital and Medical Center · Burlington, United States
    • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
    • University of Pittsburgh Cancer Institute (UPCI) · Pittsburgh, United States
    • MD Anderson in The Woodlands · Conroe, United States
    • M D Anderson Cancer Center · Houston, United States
    • MD Anderson West Houston · Houston, United States
    • MD Anderson League City · League City, United States
    • MD Anderson in Sugar Land · Sugar Land, United States
    • West Virginia University Charleston Division · Charleston, United States
    • Langlade Hospital and Cancer Center · Antigo, United States
    • Ascension Saint Elizabeth Hospital · Appleton, United States
    • Ascension Southeast Wisconsin Hospital - Elmbrook Campus · Brookfield, United States
    • Ascension Calumet Hospital · Chilton, United States
    • Ascension Saint Francis - Reiman Cancer Center · Franklin, United States
    • Ascension Columbia Saint Mary's Hospital Ozaukee · Mequon, United States
    • Ascension Columbia Saint Mary's Hospital - Milwaukee · Milwaukee, United States
    • Ascension Mercy Hospital · Oshkosh, United States
    • Ascension All Saints Hospital · Racine, United States
    • Aspirus Cancer Care - James Beck Cancer Center · Rhinelander, United States
    • Aspirus Regional Cancer Center · Wausau, United States
    • Ascension Medical Group Southeast Wisconsin - Mayfair Road · Wauwatosa, United States
    + 1 other change: verification date
  2. Oct 6, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42702214 ↗
    Enrollment 415→417
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: From date of randomization to date of death due to any cause, assessed up to 3 years → From date of registration up to two years
    Secondary outcomes 2 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedProgression free survivalFree SurvivalTime frame: From date of randomization to date of first documentation of progression or death due to any cause, assessed up to 5 years → Up to 5 years from registration
    • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 5 years → Up to 5 years after registration
    • AddedIA-PFSTime frame: From registration up to 5 years
    • AddedDistant, Locoregional, Local Failure Rates.Time frame: Up to 5 years from registration
    • Removedother outcomeChange in health-related quality of lifeTime frame: Up to 5 years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04214262
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Aug 13, 2020
Primary completion
Aug 24, 2024
Completion
Jun 9, 2027 (estimated)
Results posted
Oct 6, 2026
Last update
Nov 18, 2026

Study contacts

Megan E Daly
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atezolizumab

Start the discussion